This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
HAMBURG, Germany, Jan. 9, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) today announced that it has entered into a strategic partnership with Yale University.
Under the agreement, Evotec and Yale intend to leverage first rate science performed at Yale University together with Evotec´s drug discovery infrastructure and expertise into highly innovative discovery approaches in diseases of high unmet medical need. Initially, Evotec and Yale have defined a wide range of scientific fields including metabolic diseases, CNS, immunological diseases and cancer where they will jointly assess and potentially pursue novel assays, screens and models but in particular exploratory drug targets and compounds. The intention is to seamlessly integrate Evotec's drug discovery infrastructure with highly innovative biology at Yale to mature individual projects to a stage where they can be commercialised.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are very excited about this open innovation alliance with Yale. There is a tremendous wealth of scientific innovation at Yale that has the potential to be directly translated into first- and best-in class drug candidates. Together we want to significantly accelerate this process by removing technical bottlenecks and focusing all efforts on bringing individual projects to highest industrial standards in preparation for development and commercialisation partnerships with Pharma companies."
"This agreement is a new collaboration model between academia and the pharmaceutical industry. It essentially gives all faculties at Yale the opportunity to directly translate new biological insights into top notch drug discovery projects. Evotec is uniquely suited as a partner as they combine an extremely broad drug discovery platform with fast processes and proven commercialisation skills",
said Dr Jon Soderstrom, Managing Director of Yale's Office of Cooperative Research.
No financials were disclosed.
Founded in 1810, the Yale School of Medicine is a world-renowned centre for biomedical research, education and advanced health care. Among its 27 departments are one of the nation's oldest schools of public health and the internationally recognized Child Study Center, founded in 1911. Yale School of Medicine consistently ranks among the handful of leading recipients of research funding from the National Institutes of Health and other organizations supporting the biomedical sciences. Its core faculty of more than 1,100 physicians and scientists is well represented within the Institute of Medicine and National Academy of Sciences and among investigators of the Howard Hughes Medical Institute.